Management of Crohn’s Disease in Immunocompromised Patients After Fungemia

Biologic Therapy

The Canadian Association of Gastroenterology strongly recommends continuing vedolizumab in patients who have achieved a symptomatic response to maintain complete remission (strong recommendation, moderate‑quality evidence). 1
Vedolizumab is advised as maintenance therapy for moderate‑to‑severe Crohn’s disease because of its established efficacy and favorable safety profile, which is especially important in immunocompromised individuals. 1
The gut‑selective mechanism of vedolizumab (α4β7 integrin blockade) offers a theoretical safety advantage over systemic immunosuppression and is preferred to anti‑TNF agents in older patients where infection and malignancy risks are heightened. 3

The 2024 American Gastroenterological Association (AGA) Clinical Practice Update requires regular malnutrition screening for all IBD patients, assessing unintended weight loss, edema, and loss of muscle mass. (moderate‑quality evidence) 4
Total parenteral nutrition (TPN) should be continued with close monitoring and optimization by a registered dietitian in patients with chronic intestinal failure secondary to Crohn’s disease. (expert consensus) 4
Transition from TPN to customized hydration management (intravenous electrolyte support or oral rehydration solutions) is recommended when feasible to reduce long‑term complications. (expert consensus) 4
Glucagon‑like peptide‑2 (GLP‑2) agonists may be considered to facilitate weaning from TPN in patients with short‑bowel physiology. (expert consensus) 4
Registered dietitian involvement is essential for ongoing nutrition assessment and individualized management in complex Crohn’s disease. (expert consensus) 4
Exclusive enteral nutrition can be used as an adjunctive therapy for malnourished Crohn’s disease patients, although its applicability may be limited by anatomical factors such as a colostomy. (low‑quality evidence) 5

Heightened infection monitoring is advised after recent fungemia and during ongoing immunosuppression. (expert consensus) 7
Clinicians should monitor for recurrent infection by checking for fever, new respiratory symptoms, or any change in clinical status. (expert consensus) 7

Evaluate symptomatic response to vedolizumab between 10–14 weeks after initiation to decide whether therapy modification is needed. (conditional recommendation, very low‑quality evidence) 1
The Canadian guidelines specifically endorse this 10–14 week assessment window for vedolizumab. (conditional recommendation, very low‑quality evidence) 1

Maintain close liaison with colorectal surgery teams for patients with fibrotic disease and stoma formation. (expert consensus) 5
When intestinal obstruction does not improve with medical therapy, stricturoplasty and/or resection should be considered. (moderate‑quality evidence) 8
Nutritional support before and after any future surgery is critical for patients with chronic malnutrition. (expert consensus) 5

Do not discontinue vedolizumab prematurely based solely on recent infection history; its safety profile supports continuation after appropriate antimicrobial therapy. (moderate‑quality evidence) 3
Do not neglect systematic nutritional assessment; malnutrition is frequently under‑recognized in IBD and requires ongoing dietitian‑led monitoring. (moderate‑quality evidence) 4
Do not switch biologic agents without an adequate trial; vedolizumab requires a 10–14 week period to fully assess response. (moderate‑quality evidence) 1
Avoid corticosteroids for maintenance therapy in this vulnerable population, as they are ineffective for long‑term control and increase infection risk. (moderate‑quality evidence) 9